Fulcrum Therapeutics, Inc. (FULC)Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
3.85 USD
After hours: 3.85 |
Hot Take ↕ | Aug. 22, 2026, 5:11 a.m. EDT
The investment case for Fulcrum Therapeutics is currently broken by a severe lack of financial viability and significant legal overhang. The company is burning cash aggressively with negative free cash flow and no path to profitability visible in the forward estimates, while the balance sheet offers no real safety net against dilution. This fundamental rot is compounded by a looming securities fraud investigation, which creates a binary risk: either the company is forced into a distressed restructuring or faces delisting. While the stock trades at a discount to book value, this is a value trap driven by the legal threat and operational failure, not a margin of safety. On the trading side, the options market is screaming caution, with investors buying deep puts to hedge against a continued slide rather than betting on a rebound. The recent price action shows some stabilization, but without a resolution to the legal issues or a turnaround in cash burn, the trajectory remains deeply bearish. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.552467 |
| MSTL | 0.625596 |
| AutoETS | 0.635468 |
| AutoARIMA | 0.636388 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 0.63 |
| Ljung-Box p | 0.534 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 8.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.699 |
| Market Cap | 293,744,416 |
| Forward P/E | -7.89 |
| Beta | 2.58 |
| Website | https://www.fulcrumtx.com |
As of Aug. 22, 2026, 5:11 a.m. EDT: Speculators are positioning heavily for downside protection, with massive open interest in out-of-the-money puts at the $3.00 strike for January 2027 expiration, indicating a bet on a prolonged decline or a failed catalyst. Conversely, call activity is skewed toward deep out-of-the-money strikes ($10, $15) for the same horizon, suggesting a speculative 'lottery ticket' strategy rather than a conviction in a near-term recovery. The heavy put volume relative to call volume at realistic targets implies the market expects further weakness before any potential bounce.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.39937598 |
| Address1 | 26 Landsdowne Street |
| All Time High | 33.098 |
| All Time Low | 2.25 |
| Ask | 4.78 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 3.2 - Hold |
| Average Daily Volume10 Day | 2,087,710 |
| Average Daily Volume3 Month | 2,903,153 |
| Average Volume | 2,903,153 |
| Average Volume10Days | 2,087,710 |
| Beta | 2.581 |
| Bid | 2.71 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 4.073 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.85 |
| Current Ratio | 31.351 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.87 |
| Day Low | 3.78 |
| Debt To Equity | 1.699 |
| Display Name | Fulcrum Therapeutics |
| Earnings Call Timestamp End | 1,777,291,200 |
| Earnings Call Timestamp Start | 1,777,291,200 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | -85,396,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.232 |
| Enterprise Value | -19,817,560 |
| Eps Current Year | -0.6569 |
| Eps Forward | -0.48793 |
| Eps Trailing Twelve Months | -1.21 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7224 |
| Fifty Day Average Change | 0.12759995 |
| Fifty Day Average Change Percent | 0.034278948 |
| Fifty Two Week Change Percent | -39.9376 |
| Fifty Two Week High | 15.74 |
| Fifty Two Week High Change | -11.889999 |
| Fifty Two Week High Change Percent | -0.75540024 |
| Fifty Two Week Low | 2.83 |
| Fifty Two Week Low Change | 1.02 |
| Fifty Two Week Low Change Percent | 0.36042404 |
| Fifty Two Week Range | 2.83 - 15.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,563,456,600,000 |
| Float Shares | 63,490,762 |
| Forward Eps | -0.48793 |
| Forward P E | -7.8904757 |
| Free Cashflow | -37,373,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 9 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 3.85 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -56,640,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.033469997 |
| Held Percent Institutions | 1.0338 |
| Implied Shares Outstanding | 76,297,257 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Fulcrum Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 293,744,416 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_376267397 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -84,999,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 293,744,439 |
| Number Of Analyst Opinions | 4 |
| Open | 3.82 |
| Operating Cashflow | -65,777,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 651 8851 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.85 |
| Post Market Time | 1,787,948,400 |
| Previous Close | 3.85 |
| Price Eps Current Year | -5.860862 |
| Price Hint | 4 |
| Price To Book | 0.9452492 |
| Profit Margins | 0.0 |
| Quick Ratio | 31.158 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.16667 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 3.87 |
| Regular Market Day Low | 3.78 |
| Regular Market Day Range | 3.78 - 3.87 |
| Regular Market Open | 3.82 |
| Regular Market Previous Close | 3.85 |
| Regular Market Price | 3.85 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,890,636 |
| Return On Assets | -0.19591999 |
| Return On Equity | -0.32376 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 76,297,257 |
| Shares Percent Shares Out | 0.087299995 |
| Shares Short | 6,656,924 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 6,911,811 |
| Short Name | Fulcrum Therapeutics, Inc. |
| Short Percent Of Float | 0.088199995 |
| Short Ratio | 4.75 |
| Source Interval | 15 |
| State | MA |
| Symbol | FULC |
| Target High Price | 4.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 3.5 |
| Target Median Price | 3.5 |
| Total Cash | 318,840,000 |
| Total Cash Per Share | 4.179 |
| Total Debt | 5,278,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.46795 |
| Two Hundred Day Average Change | -3.61795 |
| Two Hundred Day Average Change Percent | -0.4844636 |
| Type Disp | Equity |
| Volume | 1,890,636 |
| Website | https://www.fulcrumtx.com |
| Zip | 2,139 |